A Study to Evaluate the Treatment Patterns and Clinical Outcomes of Pazopanib Versus Sunitinib in Patients With Advanced/Metastatic Renal Cell Carcinoma

Trial Profile

A Study to Evaluate the Treatment Patterns and Clinical Outcomes of Pazopanib Versus Sunitinib in Patients With Advanced/Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2016

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2016 New trial record
    • 25 May 2016 Results presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top